• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:董凯,张利华,王洪涛,赵子明,张彦卓,印晓星.坎地沙坦酯脂质体冻干粉的制备及在大鼠体内药动学研究[J].药学研究,2018,37(5):255-258,269[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 3783次   下载 3603次 本文二维码信息
码上扫一扫!
坎地沙坦酯脂质体冻干粉的制备及在大鼠体内药动学研究
董凯,张利华,王洪涛,赵子明,张彦卓,印晓星
字体:加大+|默认|缩小-
(徐州医科大学药学院,江苏省新药研究与临床药学重点实验室,江苏 徐州 221004)
摘要:
目的 制备并评价泊洛沙姆407修饰的坎地沙坦酯脂质体(CC/PLip),考察其口服给药后在大鼠体内药动学过程。方法 用薄膜分散法制备CC/PLip,经冷冻干燥制成冻干粉。动态光散射(DLS)测定其zeta电位和粒径,透射电镜(TEM)观察其形态,超滤离心法测定包封率;采用口服给药,观察肠道粘膜渗透行为,分析药物在大鼠体内的药代动力学参数。结果 泊洛沙姆407修饰的坎地沙坦酯脂质体呈现球形,粒径为(182.67±4.10)nm,Zeta电位为(-8.98±0.19)mV,包封率为98.94%±0.60%;体外释放试验结果表明其具有明显的缓释效果;肠道粘膜渗透试验表明CC/PLip在小肠易被吸收;药动学实验中,参比坎地沙坦酯片和CC/PLip的AUC0→48h分别为(13 112.6±5 343.7)ng·h·mL-1、(19 522.8±3 973.7)ng·h·mL-1;Cmax分别为(656.8±345.0)ng·mL-1、(1 199.1±330.7)ng·mL-1;Tmax分别为(7.3±3.0)h、(2.7±1.4)h。结论 CC/PLip包封率较高,粒径较小,具有缓释效果,能提高在小肠的吸收,可显著提高在大鼠体内的生物利用度。
关键词:  泊洛沙姆407  坎地沙坦酯  脂质体  药动学
DOI:10.13506/j.cnki.jpr.2018.05.003
基金项目:
Preparation of candesartan cilexetil liposome-lyophilized powder and its pharmacokinetics study in rats
DONG Kai,ZHANG Lihua,WANG Hongtao,ZHAO Ziming,ZHANG Yanzhuo,YIN Xiaoxing
(Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy,School of Pharmacy,Xuzhou Medical University,Xuzhou 221004,China)
Abstract:
Objective To prepare and evaluate poloxamer 407 decorated liposomes of candesartan cilexetil (CC/PLip),and to investigate the pharmacokinetics in rats.Methods The CC/PLip was prepared by the film dispersion method,and the freeze-dried powder of CC/PLip was obtained by freeze drying.The zeta potential and particle size were measured by dynamic light scattering (DLS).The morphology was observed by transmission electron microscopy (TEM),and the encapsulation efficiency was measured by ultrafiltration centrifugation.Intestinal penetration in rats was carried out with FITC-loaded liposome by oral administration.Pharmacokinetics study in rats was carried out by oral administration and analysis of rats pharmacokinetic parameters.Results The CC/PLip was spherical, the mean diameter was (182.67±4.10)nm, the zeta potential was (-8.98±0.19)mV, the encapsulation efficiency was 98.94%±0.60%. In vitro release test results showed that CC/PLip had significant slow-release effects. Intestinal penetration test results showed that CC/PLip was easily to be absorbed in the small intestine.The pharmacokinetic parameters of reference preparation and CC/PLip were as follows: AUC0→48h were (13 112.6±5 343.7)ng·h·mL-1 and (19 522.8±3 973.7) ng·h·mL-1; Cmax were (656.8±345.0) ng·mL-1 and (1 199.1±330.7) ng·mL-1; Tmax were (7.3±3.0)h and (2.7±1.4)h. Conclusion The CC/PLip had the high entrapment efficiency,small particle size and slow-release effects.They can increase the uptake of candesartan cilexetil and significantly improve the bioavailability in rats.
Key words:  Poloxamer 407  Candesartan cilexetil  Liposome  Pharmacokinetic
今日访问量:2433    总访问量:55338849
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司